Tony Schwartz, PhD
Long/short equity, Growth, biotech

Celator: A Unique Drug Ratio Technology Company For Cancer

Company Overview

Celator Pharmaceuticals (NASDAQ:CPXX) is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various cancers. Their delivery platform, CombiPlex, consists of a nano-scale system that combines previously approved chemotherapy agents administered in fixed synergistic ratios. Combining drugs in fixed ratios maximizes the therapeutic response of each drug while maintaining the desired safety profile which is difficult to achieve using current combinational regimens. It allows for prolonged exposure to the drugs without increased toxic effects. CPX-351, Celator's lead formulation, consists of FDA approved Cytarabine and Daunorubicin (1:5 ratio) and is currently in a Phase 3 trial in Acute Myeloid Leukemia (AML). A positive Phase 3 trial can be achieved by demonstrating only...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details